- Home
- FHTX vs UNCY Comparison
FHTX vs UNCY Comparison
Compare FHTX & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FHTX | UNCY |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.1M | 100.6M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FHTX | UNCY |
|---|---|---|
| Price | $2.06 | $3.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $4.17 | ★ $28.40 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.32 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,909,000.00 | $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.98 | $10,044.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 36.75 | N/A |
| 52 Week Low | $1.79 | $3.35 |
| 52 Week High | $7.61 | $8.74 |
Technical Indicators
Market Signals| Indicator | FHTX | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 29.22 | 38.42 |
| Support Level | $1.79 | $3.35 |
| Resistance Level | $2.10 | $4.18 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | 0.13 | 0.03 |
| Stochastic Oscillator | 95.00 | 41.18 |
Price Performance
Historical ComparisonAbout FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.